Overview
- In the 52-week ACHIEVE-3 study of roughly 1,700 adults, orforglipron lowered HbA1c more than oral semaglutide, including 2.2 vs 1.4 percentage points at the highest tested doses.
- Participants lost about 6–8% of body weight on orforglipron versus 4–5% with oral semaglutide at diabetes-dose comparisons; the trial did not test semaglutide’s 25 mg obesity dose.
- Gastrointestinal side effects were more frequent with orforglipron, leading to 9–10% discontinuation compared with about 4–5% for semaglutide.
- The head-to-head trial spanned 131 sites across Argentina, China, Japan, Mexico, Puerto Rico and the United States.
- Lilly says it has filed in more than 40 countries, is scaling production in Huntsville, Alabama, and expects potential US regulatory action for an obesity indication in 2026, with diabetes submissions planned later in the year.